International Journal of Antimicrobial Agents
Volume 36, Issue 4 , Pages 340-342 , October 2010

Rapidly spreading CTX-M-type β-lactamase-producing Proteus mirabilis in Japan

  • Akiko Kanayama

      Affiliations

    • Department of Infection Control and Prevention, Faculty of Medicine, Toho University, 4-16-20, Omori-nishi, Ota-ku, Tokyo 143-0015, Japan
    • ,
  • Takako Iyoda

      Affiliations

    • Chemotherapy Division, Mitsubishi Chemical Medience Corporation, 3-30-1, Shimura, Itabashi-ku, Tokyo 174-8555, Japan
    • ,
  • Kaoru Matsuzaki

      Affiliations

    • Chemotherapy Division, Mitsubishi Chemical Medience Corporation, 3-30-1, Shimura, Itabashi-ku, Tokyo 174-8555, Japan
    • ,
  • Takeshi Saika

      Affiliations

    • Chemotherapy Division, Mitsubishi Chemical Medience Corporation, 3-30-1, Shimura, Itabashi-ku, Tokyo 174-8555, Japan
    • ,
  • Fumiaki Ikeda

      Affiliations

    • Chemotherapy Division, Mitsubishi Chemical Medience Corporation, 3-30-1, Shimura, Itabashi-ku, Tokyo 174-8555, Japan
    • ,
  • Yoshikazu Ishii

      Affiliations

    • Department of Microbiology and Infectious Diseases, School of Medicine, Toho University, 5-21-16, Omori-nishi, Ota-ku, Tokyo 143-8540, Japan
    • ,
  • Keizo Yamaguchi

      Affiliations

    • Department of Microbiology and Infectious Diseases, School of Medicine, Toho University, 5-21-16, Omori-nishi, Ota-ku, Tokyo 143-8540, Japan
    • ,
  • Intetsu Kobayashi

      Affiliations

    • Department of Infection Control and Prevention, Faculty of Medicine, Toho University, 4-16-20, Omori-nishi, Ota-ku, Tokyo 143-0015, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 3 3762 9247; fax: +81 3 3762 9247.

Received 19 February 2010 ,Accepted 2 June 2010.

References 

  1. Bell JM, Chitsaz M, Turnidge JD, Barton M, Walters LJ, Jones RN. Prevalence and significance of a negative extended-spectrum β-lactamase (ESBL) confirmation test result after a positive ESBL screening test result for isolates of Escherichia coli and Klebsiella pneumoniae: results from the SENTRY Asia-Pacific Surveillance Program. J Clin Microbiol. 2007;45:1478–1482
  2. Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother. 2007;59:165–174
  3. Yamasaki K, Komatsu M, Yamashita T, Shimakawa K, Ura T, Nishio H, et al. Production of CTX-M-3 extended-spectrum (-lactamase and IMP-1 metallo β-lactamase by five Gram-negative bacilli: survey of clinical isolates from seven laboratories collected in 1998 and 2000, in the Kinki region of Japan. J Antimicrob Chemother. 2003;51:631–638
  4. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Eighteenth informational supplement. Document M100-S18. Wayne, PA: CLSI; 2008.
  5. Ishii Y, Kimura S, Alba J, Shiroto K, Otsuka M, Hashizume N, et al. Extended-spectrum β-lactamase-producing Shiga toxin gene (stx1)-positive Escherichia coli O26:H11: a new concern. J Clin Microbiol. 2005;43:1072–1075
  6. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33:2233–2239
  7. Weigel LM, Anderson GJ, Tenover FC. DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilis. Antimicrob Agents Chemother. 2002;46:2582–2587
  8. Wu JJ, Ko WC, Tsai SH, Yan JJ. Prevalence of plasmid-mediated quinolone resistance determinants QnrA, QnrB, and QnrS among clinical isolates of Enterobacter cloacae in a Taiwanese hospital. Antimicrob Agents Chemother. 2007;51:1223–1227
  9. Yoshida I, Fujimura T, Itoh Y, Tachibana M, Kaku M, Kanemitsu K, et al. Antimicrobial susceptibility of clinical isolates of aerobic Gram-negative bacteria in 2004. Jpn J Chemother. 2008;56:562–579
  10. Ho PL, Ho AYM, Chow KH, Wong RCW, Duan RS, Ho WL, et al. Occurrence and molecular analysis of extended-spectrum β-lactamase-producing Proteus mirabilis in Hong Kong, 1999–2002. J Antimicrob Chemother. 2005;55:840–845
  11. Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ, James D, et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimicrob Chemother. 2004;54:735–743
  12. Saito R, Sato K, Kumita W, Inami N, Nishiyama H, Okamura N, et al. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis. J Antimicrob Chemother. 2006;58:673–677

PII: S0924-8579(10)00239-6

doi: 10.1016/j.ijantimicag.2010.06.002

International Journal of Antimicrobial Agents
Volume 36, Issue 4 , Pages 340-342 , October 2010

Article Tools